Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
Clinical and Corporate HighlightsSuccessfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company's evolutionStrengthened balance sheet through completion of a $7.5 million private placement to support continued clinical advancementReported positive preclinical safety and tolerability data supporting dose selection for the upcoming Phase 2a clinical trial evaluating Nu-3 Gel in infected diabetic foot ulcers (iDFUs)Announced internationally recognized diabetic foot expert David G. Armstrong, DPM, MD, Ph.D., as Study Chair and Scientific Advisor for the Phase 2a clinical programExpanded global intellectual property portfolio with a n
